Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs Moderna, Inc. — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $77, while Moderna, Inc. trades at $63.72 (market cap $24.18B). The key difference: JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| JPIN | MRNA | |
|---|---|---|
52-Week High | $77.00 | $81.80 |
52-Week Low | $64.96 | $22.36 |
Market Cap | — | $24.18B |
Sector | — | Health |
Enterprise Value | — | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN trades at $76.515, up 0.2% today, with technical indicators signaling a bullish trend from moving averages but caution from overbought RSI levels. The ETF, launched in 2014, provides exposure to foreign large-cap value stocks, with a dividend scheduled for June 2026. Recent news highlights its smart beta strategy and broad market category focus.
The outlook remains positive due to strong technical momentum and diversified international equity exposure, though overbought conditions and reliance on global markets pose risks. Investors benefit from value-oriented strategies but should monitor international economic volatility for potential impacts on performance.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
